The US market for interventional oncology devices continues to grow, driven by expanding treatable patient populations and increasing uptake of premium-priced technology. However, growth in this market will be hindered to some extent by mixed clinical data, which has somewhat deterred adoption of interventional oncology devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.
The dynamic patient population eligible for interventional oncology procedures supports growth in the ablation device and embolization particle markets.
How have approved indications changed in recent years?
What are the fastest growing patient populations eligible for interventional oncology treatments?
What is the clinical evidence supporting the use of ablation or embolization particles in various types of cancer?
Microwave ablation devices and niche technologies, such as IRE, are rising in popularity among interventional oncologists.
How does the uptake of microwave ablation and IRE devices affect other types of ablation devices?
In which indications will these newer ablation devices experience the fastest adoption?
How can companies in the fragmented microwave ablation market gain a competitive advantage?
Growth in the premium-priced embolization particle segments, such as the DEBs and radioembolization sphere spaces, has slowed in recent years.
What factors has contributed to the slowing growth in these markets?
What are challenges facing physicians and competitors in this space?
How has M&A activity shaped the competitive embolization particles market in recent years?
- Interventional Oncology Devices - Market Insights - United States
Author(s): Bishwjit Ghoshal, MBA
Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.
Follow Bishwjit on twitter: @Bishwjit_DRG